Many people who stop Mounjaro, an injectable weight-loss drug, not only regain the weight, but also lose the related health benefits, according to a new study published in the scientific journal JAMA Internal Medicine. Its active substance, tirzepatide, helps people lose up to 20% of their body weight within 72 weeks (1.5 years).
All participants in the study received tirzepatide for 36 weeks, together with support in diet and exercise, before being randomly divided into two groups. One continued the drug for another 52 weeks, while the other switched to placebo for the same period. Both the participants and the researchers did not know then who belonged to which group.
Mounjaro achieves weight loss by reducing appetite, stabilizing blood sugar, and enhancing fat burning.
The team focused on the results of 308 participants who had lost at least 10% of their body weight at the end of the initial period before they took placebp. They found that one year after stopping it, 82% of these participants had regained 25% or more of their lost weight, while at the same time the greater the weight gain, the greater the burden on health issues such as blood pressure, bad cholesterol, and blood sugar.
Experts say that this happens because the drug does not automatically change patients’ habits in diet and exercise, and if this is not achieved, the benefits of the treatment cannot be maintained after it ends.
Source: Guardian
What is fyi.news?
